IDH1 and glioma: For example, pushing the cells towards a particular state could unlock a specific vulnerability which could be exploited via a combination therapy, a strategy that has been proposed as “differentiation therapy.”63,64 In the case of IDH-Mut and H3K27M-Mut gliomas, this would involve targeting the putative glioma stem cells (GSCs) that underlie tumor progression and resistance to therapy.